ALTH
Allos Therapeutics Inc
Biopharmaceutical company focused on development and commercialization of cancer therapies, notably FOLOTYN (pralatrexate) for peripheral T-cell lymphoma
CUSIP: 019777101HealthcareUS1 holder
Allos Therapeutics Inc
Biopharmaceutical company focused on development and commercialization of cancer therapies, notably FOLOTYN (pralatrexate) for peripheral T-cell lymphoma
No insider transactions reported in the last 6 months. Look across all recorded history →